Market Overview

Nanosphere Wins FDA Clearance for C. difficile Test

Related NSPH
Morning Market Losers
Morning Market Movers

Nanosphere, Inc. (Nasdaq: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today the U.S. Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its C.difficile test on the automated sample-to-result Verigene® System.

The C. difficile test expands Nanosphere's infectious disease test capabilities. C. difficile infection is a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death. In less than two hours, the C. difficile test detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain which is associated with increased severity of disease and used for infection control. Early and accurate diagnosis of C. difficile infections is critical in both the proper treatment of infected patients and subsequent implementation of isolation and containment procedures to prevent further spread of the infection.

Posted-In: News FDA

 

Related Articles (NSPH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters